BioNTech vs Guardant Health

BioNTech (BNTX), health care, and Guardant Health (GH), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

BioNTech is worth $21B on the stock market and Guardant Health $19.4B: BioNTech is valued at 9% more. BioNTech's operating margin in its latest fiscal year was -49.0% and Guardant Health's -44.5%. Over the past year BioNTech's share price has moved -16.8% and Guardant Health's +50.7%.

Key facts

BioNTech market value
$21B
Guardant Health market value
$19.4B
BioNTech revenue
$3.2BFY to 2025-12-31
Guardant Health revenue
$982MFY to 2025-12-31
Superinvestors holding both
1

Market values as of .

BioNTech vs Guardant Health: every measure side by side
Measure BioNTech Guardant Health
SectorHealth CareHealth Care
Country Germany United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$21Bhigher$19.4Blower
Revenue$3.2Bhigher$982Mlower
Earnings-$1.3Blower-$416.3Mhigher
Employees7,807higher2,490lower
Total assets$24.4Bhigher$2Blower
Valuation
P/E——
P/S6.6lower19.7higher
P/B——
Dividend yield—0.00%
Profitability
Operating margin-49.0%lower-44.5%higher
Balance sheet
Net assets$21.3Bhigher-$99.3Mlower
Total liabilities$3.1Bhigher$2.1Blower
Total debt—$1.5B
Cash on hand$8.5Bhigher$378.2Mlower
Price change
Today-0.47%higher-0.52%lower
1 year-16.8%lower+50.7%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": BioNTech / Guardant Health). Who owns BNTX · Who owns GH

Further comparisons

Learn

Questions and answers

Which is bigger, BioNTech or Guardant Health?

By market value, BioNTech is the larger: $21B against $19.4B for Guardant Health. By revenue in its latest fiscal year, BioNTech is the larger: $3.2B against $982M for Guardant Health.

Which has the higher operating margin?

Guardant Health: -44.5%, against -49.0% for BioNTech. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which superinvestors own both BioNTech and Guardant Health?

In their latest 13F filings, Temasek holds both.

Cite this page

Funkfolio, “BioNTech vs Guardant Health”, data as of 17 November 2026. https://funkfolio.com/compare/bntx-vs-gh

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.